[Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women].

Abstract

OBJECTIVE:

To study the efficacy of alendronate to prevent hip fracture risk of postmenopausal women.

METHODS:

Randomized controlled trials in postmenopausal women receiving alendronate or placebo for preventing hip fractures rate were searched from Medline, EMBASE, Cochrane Trial Registry and China Biological Medicine database between January 1980 to December 2007. Key words included hip fractures, alendronate, postmenopausal and placebo-controlled. Language was limited in English and Chinese. The software Revman 4.2 was used to perform meta-analysis.

RESULTS:

Six trials, which included 8610 postmenopausal women, met all our inclusion criteria Meta-analysis showed that alendronate can decrease hip fracture rate (OR = 0.51, 95% CI: 0.34, 0.77).

CONCLUSION:

Alendronate can reduce significantly hip fracture rate in postmenopausal women.

• Authors: Ting Yuan, Xiao-lin Li, Chang-qing Zhang, Hui-peng Shi, Bing-fang Zeng
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 89 Issue 23 Pg. 1620-2 (Jun 16 2009) ISSN: 0376-2491 [Print] China
• PMID: 19957509 (Publication Type: English Abstract, Journal Article, Meta-Analysis)

Chemical References

• Bone Density Conservation Agents
• Alendronate

Topics

• Alendronate (therapeutic use)
• Bone Density Conservation Agents (therapeutic use)
• Female
• Hip Fractures (prevention & control)
• Humans
• Postmenopause
• Randomized Controlled Trials as Topic
• Treatment Outcome